Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service decompression & minimally invasive spine cases in Iowa: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (250 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 27 | 1,410 | 24% |
| 2020 | 26 | 1,271 | 27% |
| 2021 | 28 | 1,415 |
Laminotomy, laminectomy, interspinous devices; the MIS call point. Professional codes (what the surgeon bills): CPT 63030, 63047, 63020, 63045, 22867; the hospital bills MS-DRG 518, 519, 520.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 72% of the cases CMS names in Iowa; 13 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Lumbar fusion | 25 | 1,087+7%/yr | +7%/yr | 2.40.9× | 0% | 1,670 in 2030+7.4%/yr |
| Cervical fusion & disc arthroplasty |
Decompression & minimally invasive spine in every state, and its device makers · Every procedure market in Iowa · Every state · Compare with Ohio
| 2024 |
| 1,138 |
| 40% |
| 2025 est. | ≈ 990 | – |
| 2026 est. | ≈ 1,020 | – |
| 30% |
| 2022 | 26 | 1,153 | 34% |
| 2023 | 23 | 1,144 | 38% |
| 2024 | 23 | 1,138 | 40% |
| 2025 from claims | – | 994 912–1,051 | 41% |
| 2026 forecast | – | 1,020 898–1,178 | 40% |
| 2027 forecast | – | 1,029 879–1,226 | 40% |
| 2028 forecast | – | 1,037 865–1,270 | 41% |
| 2029 forecast | – | 1,045 854–1,311 | 41% |
| 2030 forecast | – | 1,053 844–1,350 | 42% |
In 2025, 43% inpatient hospital, 50% hospital outpatient, 7% surgery center. The share outside the hospital has moved +6 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| 3,603−6.4%/yr |
| −6.4%/yr |
| 2.5 |
| 7% |
| 3,990 in 2030+1.7%/yr |
| Michigan | 55 | 2,499−11%/yr | −11%/yr | 2.8 | 7% | 2,340 in 2030−1.1%/yr |
| Indiana | 65 | 2,388−6%/yr | −6%/yr | 3.3 | 5% | 2,460 in 2030+0.5%/yr |
| Missouri | 56 | 2,193−7.1%/yr | −7.1%/yr | 3.4 | 5% | 2,190 in 20300%/yr |
| Kansas | 33 | 1,688−5.7%/yr | −5.7%/yr | 4.1 | 1% | 1,840 in 2030+1.4%/yr |
| Minnesota | 40 | 1,579−8.6%/yr | −8.6%/yr | 3.3 | 9% | 1,920 in 2030+3.3%/yr |
| Wisconsin | 46 | 1,360−6.9%/yr | −6.9%/yr | 2.3 | 5% | 1,720 in 2030+4%/yr |
| Nebraska | 23 | 974−3.8%/yr | −3.8%/yr | 3.7 | 9% | 890 in 2030−1.4%/yr |
| South Dakota | 18 | 528−7.2%/yr | −7.2%/yr | 4.0 | 0% | 760 in 2030+6.2%/yr |
| North Dakota | 9 | 384−6.4%/yr | −6.4%/yr | 3.8 | 13% | 320 in 2030−3.1%/yr |
| 9 |
| 408+2.6%/yr |
| +2.6%/yr |
| 0.90.6× |
| 3% |
| 500 in 2030+3.4%/yr |
| Kyphoplasty & vertebroplasty | 2 | 213−11%/yr | −11%/yr | 0.50.3× | 0% | 130 in 2030−7.9%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Globus Medical leads with 44% of company spending on these surgeons in 2025, +43 pts on 2024.
In 2025, 6 companies reported engagement with Iowa’s surgeons worth $21K in consulting, speaking, meals and travel tied to these products, about $903 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.